Department of Medicine – University of Pamplona

HeartBeam Announces Expansion of Its Scientific Advisory Board

Retrieved on: 
Thursday, November 9, 2023

HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.

Key Points: 
  • HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only credit card-size 3D-vector electrocardiogram (VECG) platform for patient use at home, allowing for the creation of rich data for AI, today announced the expansion of its Scientific Advisory Board (SAB) to include several leading cardiologists.
  • He is a world-renowned expert in interventional cardiology, and an accomplished inventor, entrepreneur, and investment fund founder.
  • “We are honored and pleased to have such a distinguished group of physicians joining our Scientific Advisory Board,” said Branislav Vajdic, Ph.D., CEO and Founder of HeartBeam.
  • “HeartBeam will benefit tremendously from the input of these leaders in interventional cardiology, electrophysiology, clinical research, and new technologies.

First in the U.S! Palliative Care VR Educational Material by Jolly Good and Emergency Medicine Specialists

Retrieved on: 
Monday, November 6, 2023

TOKYO, Nov. 6, 2023 /PRNewswire/ -- Jolly Good US Inc. (Brookline, Massachusetts, USA CEO: Kensuke Joji), a developer of medical VR, is pleased to announce that it has developed the first "Palliative Care Communication (*1) Training VR" in the United States in collaboration with Brigham and Women's Hospital, a Harvard affiliated hospital. In addition, using this VR, we will hold a medical VR seminar at "GSA2023", Gerontological Society of America.

Key Points: 
  • In addition, using this VR, we will hold a medical VR seminar at "GSA2023", Gerontological Society of America.
  • Therefore, Jolly Good US Inc. decided to jointly develop this product because we believe that training medical professionals on communication in palliative care by using VR, they can efficiently and effectively acquire communication skills.
  • He will give a lecture on training assessment skills, a basic skill for palliative care by using the jointly developed VR.
  • Unfortunately, opportunities to learn this palliative care communication skill are rare for non-palliative care clinicians due to training personnel, time, and cost.

Generate:Biomedicines and Roswell Park Comprehensive Cancer Center Enter into a Collaboration Agreement to Accelerate Novel Cell Therapies for Oncology Using Generative AI

Retrieved on: 
Wednesday, November 1, 2023

In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.

Key Points: 
  • In ovarian cancer alone, an estimated 314,000 women worldwide are diagnosed and over 200,000 women die each year.
  • View the full release here: https://www.businesswire.com/news/home/20231101307318/en/
    Under the collaboration agreement, Generate:Biomedicines and Roswell Park will contribute toward creating optimized cell therapies, where a patient’s T cells are engineered to recognize and kill tumors.
  • The collaboration combines the programmability and scalability of The Generate Platform and Roswell Park’s expertise in cell therapy design, clinical development, and manufacturing to bring best-in-class cell therapies to patients.
  • It is anticipated that Roswell Park will serve as a site and recommend lead investigators for Phase I and II clinical trials.

Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D.

Retrieved on: 
Tuesday, October 31, 2023

Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.

Key Points: 
  • Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.
  • Dr. Armitage has served as President of both the American Society for Transplantation and Cellular Therapy (ASTCT) and the American Society of Clinical Oncology (ASCO).
  • “We are deeply honored to have Dr. Armitage join Syncromune’s Scientific Advisory Board as chair,” stated Eamonn Hobbs, President and CEO of Syncromune.
  • He has authored or co-authored more than 600 articles and 100 book chapters and is the editor/co-editor of 27 books.

Aclarion Announces Nociscan® Cost-Effectiveness Poster Presented at 45th Annual SMDM Meeting

Retrieved on: 
Tuesday, October 24, 2023

The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023.

Key Points: 
  • The 45th Annual Society for Medical Decision Making (SMDM) Meeting is being held October 22-25, 2023.
  • Founded in 1979, SMDM promotes scientific and methodological rigor in health care decision research and its application to health policy and clinical care.
  • “We are pleased with the compounding interest in the Nociscan cost-effectiveness research,” said Ryan Bond, Chief Strategy Officer at Aclarion.
  • In July 2023, a Nociscan cost-effectiveness poster was presented at the American Society for Pain & Neuroscience (ASPN) annual meeting.

Two NYU Langone Health Faculty Elected to National Academy of Medicine

Retrieved on: 
Tuesday, October 24, 2023

NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Céline R. Gounder, MD, ScM , and Robert Montgomery, MD, DPhil , two innovators at NYU Langone, have been elected to the National Academy of Medicine, one of the highest honors in their field.

Key Points: 
  • NEW YORK, Oct. 24, 2023 /PRNewswire/ -- Céline R. Gounder, MD, ScM , and Robert Montgomery, MD, DPhil , two innovators at NYU Langone, have been elected to the National Academy of Medicine, one of the highest honors in their field.
  • In a statement, the academy recognized her "for being one of the world's leading experts in communication about science, medicine, and public health.
  • Dr. Montgomery, is the H. Leon Pachter, MD, Professor of Surgery, chair of the Department of Surgery at NYU Grossman School of Medicine, and director of the NYU Langone Transplant Institute .
  • The academy addresses critical issues in health, science, medicine, and related policy and inspires positive actions across sectors.

Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

Retrieved on: 
Tuesday, October 17, 2023

(1)

Key Points: 
  • (1)
    The multi-center, open label, dose escalation clinical trial will assess the safety and clinical activity of NKX019 in patients with refractory LN.
  • “The clearance of Nkarta’s IND for NKX019 in lupus nephritis is an important achievement for Nkarta, and we feel NK cell therapy is ideally suited for the treatment of autoimmune disease,” said Paul J. Hastings, President and CEO of Nkarta.
  • Nkarta announced today the opening of a new cohort in its Phase 1 study of NKX019 in r/r NHL.
  • Nkarta management will discuss its program in autoimmune disease and other corporate updates on Tuesday, October 17, at 8:00 a.m.

IMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board

Retrieved on: 
Friday, October 6, 2023

LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.

Key Points: 
  • LAWRENCEVILLE, N.J., Oct. 06, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing non-viral DNA-mediated immunotherapy and next-generation vaccines, announces the appointment of Patrick Ott, M.D., Ph.D. to the Company’s scientific advisory board.
  • Dr. Ott is the Clinical Director of the Melanoma Disease Center and the Director, Clinical Sciences, of the Center for Immuno-Oncology at the Dana-Farber Cancer Institute.
  • He joins current scientific advisory board members Dan H. Barouch, M.D., Ph.D., Luke D. Handke, Ph.D., Sachet A. Shukla, Ph.D. and John W. Shiver, Ph.D.
    “We are honored that Dr. Ott has agreed to our scientific advisory board and believe that he will offer invaluable guidance as we further develop our technologies and advance our pipeline,” said Dr. Corinne Le Goff, president and chief executive officer of IMUNON.
  • Dr. Ott has been Principal Investigator of a first-in-human clinical trial testing a personalized vaccine (NeoVax) in patients with melanoma.

What Is the Impact of Predictive AI in the Health Care Setting? Findings underscore the need to track individuals affected by machine learning predictions.

Retrieved on: 
Monday, October 9, 2023

NEW YORK, Oct. 9, 2023 /PRNewswire-PRWeb/ -- Models built on machine learning in health care can be victims of their own success, according to researchers at the Icahn School of Medicine and the University of Michigan.

Key Points: 
  • Their study assessed the impact of implementing predictive models on the subsequent performance of those and other models.
  • Their study assessed the impact of implementing predictive models on the subsequent performance of those and other models.
  • "These findings are equally applicable outside of health care settings and extend to predictive models in general.
  • The paper is titled "Implications of the Use of Artificial Intelligence Predictive Models in Health Care Settings: A Simulation Study."

Flagship Pioneering Appoints John Lepore as CEO-Partner and CEO of ProFound Therapeutics

Retrieved on: 
Monday, October 2, 2023

CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced that John Lepore, M.D., will join Flagship Pioneering as CEO-Partner, and ProFound as Chief Executive Officer, effective October 16, 2023.

Key Points: 
  • CAMBRIDGE, Mass., Oct. 2, 2023 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and ProFound™ Therapeutics, a company pioneering the discovery of a vastly expanded human proteome and using its newfound insights to unlock a universe of potential new medicines, today announced that John Lepore, M.D., will join Flagship Pioneering as CEO-Partner, and ProFound as Chief Executive Officer, effective October 16, 2023.
  • Dr. Lepore joins ProFound after 17 years at GSK where he had extensive experience leading large international R&D organizations across diverse therapeutic areas.
  • "We've made significant advances with our ProFoundry™ Platform, which is a wellspring of first-in-class therapeutic opportunities," said Avak Kahvejian, Ph.D., Flagship Pioneering General Partner and Founding CEO of ProFound Therapeutics.
  • "I'm honored to join the outstanding team at Flagship Pioneering and to have the opportunity to lead the talented team at ProFound who are redefining what we know about human biology with the ProFoundry Platform," said John Lepore, M.D., CEO of ProFound Therapeutics and Flagship Pioneering CEO-Partner.